Skip to main content

Table 1 Patient characteristics

From: A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy

 12345678910
Age (year)69745745746376687371
Gender (M/F)MMFMMFFMFF
PrimaryLungPancreasIleumIleumUnknownMTC*IleumPancreasUnknownIleum
Grade21121NA2111
MIB-13-20%2%1%1%1%NA5%2%1%2%
Ki-67NA2-5%3%2%0NA5%0%0%1%
Resection primaryYNYYNYNNYY
Liver embolizationNYYYNNNNNN
SSA therapyYYYYYNNYYY
Chemo/targeted therapyNNNNNNNYNN
Metastatic sidesLiver, LN, bone, otherLiver, LN, boneLiver, LN, boneLiver, otherLiver, LN, bone, otherLNLiver, LN, bone, otherLiver, LN, otherLiver, LN, bone, otherLiver, LN, bone, other
Tumour lesions includedNoneLiver: 3
Other: 1
Liver: 2
Other: 1
Liver: 2Liver: 2
Other: 2
Other: 1Liver: 4
Other: 1
Liver: 5
Other: 1
Liver: 1
Other: 1
Liver: 2
Administered activity (MBq)7131725371767271718872127613747673387373
  1. *Medullar thyroid carcinoma
  2. LN lymph nodes; NA not available; SSA therapy somatostatin analogue use during PRRT treatment
  3. *†Age at start PRRT